Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2016—Oxford Gene Technology has expanded its catalog of fluorescence in situ hybridization products with nine Cytocell Aquarius probes: ETV6 Proximal Probe Green, ETV6 Distal Probe Red, MPO Probe Red, TP53 Probe Green, NUP214 Probe Red, DEK Probe Green, TAS2R1 (5p15.31) Probe Green, Chromosome 9 Satellite III Probe Aqua, and Chromosome 15 Alpha Satellite Probe Red.
September 2016—Genomic Health and Epic Sciences announced an exclusive agreement to commercialize Epic Sciences’ novel AR-V7 liquid biopsy test in the U.S. through Genomic Health’s commercial channel. The blood-based test detects the V7 variant of the androgen receptor protein in the nucleus of circulating tumor cells—information that can help guide treatment selection in patients with metastatic castration-resistant prostate cancer.
September 2016—SpeeDx received CE-IVD marking for its PlexPCR HSV-1&2, VZV multiplex qPCR kit. The multiplex molecular diagnostic test offers a single-well solution to cover the detection and differentiation of three herpes viruses (HSV-1, HSV-2, VZV) in addition to an internal control.
September 2016—Leica Biosystems added four sizes of Surgipath AffirmSeal jars. The new sizes, 40 mL, 60 mL, 90 mL, and 120 mL, are offered in multiple packaging configurations. Prefilled with 10 percent neutral buffered formalin, the jars are specifically designed for safe collection and transport of various sized specimens.
September 2016—The Oncomine Lung Cell-Free DNA Assay from Thermo Fisher Scientific is designed to target mutations in non-small cell lung cancer samples derived from circulating cfDNA in blood.
September 2016—Thermo Scientific introduced two large-capacity blood banking centrifuge models. For regular- to medium-throughput blood processing needs, the Sorvall BP 8 and Heraeus Cryofuge 8 centrifuges provide 6 × 550 mL blood bag capacity and, using the same bucket system, are upgradeable to 8 × 550 mL bags.
September 2016—Aesku Group has received FDA 510(k) clearance for its Helios Automated IFA System with Aeskuslides ANA HEp-2-Gamma Assay.
September 2016—Roche announced the worldwide launch of the Heat-Seq Target Enrichment Systems, which provide rapid and accurate enrichment methods designed to improve the detection of variants in human genetics and cancer research.
September 2016—BrandTech introduced a line of Blaubrand class A, USP-certified volumetric glassware from Brand GmbH & Co. KG. The line includes clear and amber volumetric flasks, graduated cylinders, bulb pipettes, and volumetric pipettes.
September 2016—Astute Medical said in a statement that a new ancillary analysis of two multicenter studies using the company’s NephroCheck Test demonstrates that urine insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases 2 (TIMP-2), the biomarkers detected and measured by the test, accurately predict acute kidney injury in septic patients with or without other organ failures.
